Home › Companies › Arbutus Biopharma Corporation › 2025-2026

Arbutus Biopharma Corporation 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arbutus Biopharma Corporation’s Form 8-K, filed 2026-05-27 (Item 5.07 on EDGAR). Page generated 04 October 2026.

8Reported items
148Asset managers
1,267Fund votes
2026-05-26Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arbutus Biopharma Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arbutus Biopharma Corporation

These tallies are Arbutus Biopharma Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-27 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arbutus Biopharma Corporation — official shareholder meeting results, meeting held 2026-05-26
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Lindsay Androski, JD, MBA, CFA	136,780,089	--	--	9,693,538	22,829,831	Majority: yes
Elect Director: Robert Alan Beardsley	138,456,756	--	--	8,016,871	22,829,831	Majority: yes
Elect Director: Joseph Bishop	137,372,240	--	--	9,101,387	22,829,831	Majority: yes
Elect Director: Matthew Gline	126,670,273	--	--	19,803,354	22,829,831	Majority: yes
Elect Director: Roger Sawhney, MD	139,299,405	--	--	7,174,222	22,829,831	Majority: yes

Source: Arbutus Biopharma Corporation, Form 8-K, filed with the SEC on 2026-05-27 — read the filing on EDGAR.

How asset managers voted at the Arbutus Biopharma Corporation 2025-2026 meeting

Each item below shows how the 148 asset managers that disclosed a Arbutus Biopharma Corporation vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arbutus Biopharma Corporation’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT/CIRCULAR; AND

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 145 asset managers below cast 99% of the shares they voted on this item FOR (91,272,506 for, 1,158,275 against).

FOR: 91,272,506 (98.7%)AGAINST: 1,158,275 (1.3%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN ” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Morgan Stanley	31,433,738	0	0	For
Two Seas Capital LP	14,717,397	0	0	For
BlackRock	9,791,590	33,074	0	For
Vanguard	9,236,251	25	1	For
State Street	5,551,939	23,979	0	For
Charles Schwab	2,800,381	0	0	For
Legal & General Investment Management Ltd	2,370,471	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,117,957	0	0	For
Fidelity	1,897,294	0	0	For
Equitable	1,651,258	0	0	For
ADAR1 Capital Management, LLC	1,627,678	0	0	For
Rubric Capital Management LP	1,265,390	0	0	For
Northern Trust	956,029	16,948	0	For
Deltroit Asset Management (UK) LLP	800,000	0	0	For
UBS	0	741,177	0	Against
Rangeley Capital, LLC	353,501	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	301,741	0	0	For
Wellington	290,344	0	0	For
Nuveen	259,017	0	0	For
TIAA	256,883	0	0	For
MELLON INVESTMENTS Corp	256,841	0	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	0	For
Invesco	0	224,047	0	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	216,239	0	0	For
Western Standard LLC	215,038	0	0	For

Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.

2. TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;

COMPENSATION

Combines 2 wordings of this item as funds reported it.

99.4% fund support · no official result

FOR 99.4%

The 39 asset managers below cast 99.4% of the shares they voted on this item FOR (29,164,826 for, 162,628 against).

FOR: 29,164,826 (99.4%)AGAINST: 162,628 (0.6%)

Largest asset managers voting on “TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	7,980,229	13,287	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
Deltroit Asset Management (UK) LLP	800,000	0	For
Rangeley Capital, LLC	353,501	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	0	148,531	Against
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

3. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 137,372,240WITHHELD: 9,101,387

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Joseph Bishop”): 137,372,240 for, 9,101,387 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 197,537,710 outstanding shares: 70% for, 5% withheld (74% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (27,898,121 for, 0 against).

FOR 99.0%

FOR: 27,898,121 (99.0%)ABSTAIN: 275,832 (1.0%)

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,987,215	6,301	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	0	256,883	Abstain
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 136,780,089WITHHELD: 9,693,538

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 136,780,089 for, 9,693,538 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 197,537,710 outstanding shares: 69% for, 5% withheld (74% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (28,161,275 for, 0 against).

FOR 99.9%

FOR: 28,161,275 (100.0%)ABSTAIN: 12,678 (0.0%)

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,486	30	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%

FOR: 126,670,273WITHHELD: 19,803,354

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Matthew Gline”): 126,670,273 for, 19,803,354 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 197,537,710 outstanding shares: 64% for, 10% withheld (74% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (22,059,662 for, 0 against).

FOR 78%ABSTAIN 22%

FOR: 22,059,662 (78.3%)ABSTAIN: 6,114,291 (21.7%)

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,987,214	6,302	For
Morgan Stanley	6,182,656	0	For
BlackRock	0	4,907,707	Abstain
State Street	2,680,508	0	For
Fidelity	1,693,046	63,331	For
Equitable	1,404,832	246,426	For
Charles Schwab	1,399,892	0	For
TIAA	0	256,883	Abstain
QUANTITATIVE MASTER SERIES LLC	0	248,061	Abstain
Invesco	0	148,531	Abstain
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	0	70,920	Abstain
ETFis Series Trust I	57,895	0	For
Pacific Life	0	51,981	Abstain
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	0	40,001	Abstain
Bridge Builder Trust	0	32,901	Abstain
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 138,456,756WITHHELD: 8,016,871

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 138,456,756 for, 8,016,871 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 197,537,710 outstanding shares: 70% for, 4% withheld (74% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (28,173,929 for, 0 against).

FOR 99.9%

FOR: 28,173,929 (100.0%)ABSTAIN: 24 (0.0%)

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,492	24	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

7. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Roger Sawhney, MD

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 139,299,405WITHHELD: 7,174,222

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Roger Sawhney, MD”): 139,299,405 for, 7,174,222 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 197,537,710 outstanding shares: 71% for, 4% withheld (74% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (28,173,931 for, 0 against).

FOR 99.9%

FOR: 28,173,931 (100.0%)ABSTAIN: 22 (0.0%)

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,494	22	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

8. TO APPROVE THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 37 asset managers below cast 99.9% of the shares they voted on this item FOR (28,173,946 for, 3 against).

FOR: 28,173,946 (100.0%)AGAINST: 3 (0.0%)ABSTAIN: 4 (0.0%)

Largest asset managers voting on “TO APPROVE THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE F” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,993,509	3	4	For
Morgan Stanley	6,182,656	0	0	For
BlackRock	4,907,707	0	0	For
State Street	2,680,508	0	0	For
Fidelity	1,756,377	0	0	For
Equitable	1,651,258	0	0	For
Charles Schwab	1,399,892	0	0	For
TIAA	256,883	0	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	0	For
Invesco	148,531	0	0	For
Lincoln Financial	102,200	0	0	For
Goldman Sachs	99,139	0	0	For
ProShares	86,900	0	0	For
AIG/SunAmerica	80,331	0	0	For
Northern Trust	75,298	0	0	For
Global X	70,920	0	0	For
ETFis Series Trust I	57,895	0	0	For
Pacific Life	51,981	0	0	For
Brighthouse	48,336	0	0	For
John Hancock	42,237	0	0	For
Nationwide	40,001	0	0	For
Bridge Builder Trust	32,901	0	0	For
Voya	28,676	0	0	For
Direxion Shares ETF Trust	28,437	0	0	For
DWS	21,573	0	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Largest Arbutus Biopharma Corporation shareholders voting in 2025-2026

Ranked by the number of Arbutus Biopharma Corporation shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 197,537,710 shares outstanding at the time of that meeting.

Top Arbutus Biopharma Corporation shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Morgan Stanley	15.91%
2	Two Seas Capital LP	7.45%
3	BlackRock	4.97%
4	Vanguard	4.68%
5	State Street	2.82%
6	Charles Schwab	1.42%
7	Legal & General Investment Management Ltd	1.20%
8	GEODE CAPITAL MANAGEMENT, LLC	1.07%
9	Fidelity	0.96%
10	Equitable	0.84%

Reported Arbutus Biopharma Corporation ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Arbutus Biopharma Corporation beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Matthew Gline	19.67%	DEF14A
Roivant Sciences Ltd.	19.67%	DEF14A
Morgan Stanley	13.52%	13F
Entities affiliated with Morgan Stanley	13.12%	DEF14A
Two Seas Capital LP	9.39%	13G
Entities affiliated with Whitefort Capital Management, LP	7.56%	DEF14A
BlackRock	6.56%	13F
Entities affiliated with Two Seas Capital LP	6.37%	DEF14A
Entities affiliated with Blackrock, Inc.	5.26%	DEF14A
Vanguard Group	4.68%	13F

Percentages above are of 197,537,710 shares outstanding, as reported by Arbutus Biopharma Corporation on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arbutus Biopharma Corporation’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Arbutus Biopharma Corporation's shareholder meeting held 2026-05-26, in the 2025-2026 proxy season, 148 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,267 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Arbutus Biopharma Corporation's own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS… — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Arbutus Biopharma Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).